Avina Singh, MD
Basic profileMetro-Minnesota Community Oncology Research Consortium
Avina Singh is an Oncology physician affiliated with Metro-Minnesota Community Oncology Research Consortium. OpenAlex indexes 8 publications with 1,583 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Allergan, Inc.Program year20221 payment
- E.R. Squibb & Sons, L.L.C.Program year20221 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
41.2%Substance P/Neurokinin-1 Receptor Antagonist36.7%Aprepitant100%Part B, office-administered≥36 patientsSerotonin-3 Receptor Antagonist4.3%Palonosetron hcl72%Granisetron hydrochloride27%Ondansetron Hcl1%Part D + Part B<11 patients+ 4 more classes in this area
Cancer & immunology
30.3%PD-1 inhibitor26.9%Pembrolizumab100%Part B, office-administered≥18 patientsAromatase Inhibitor1.2%Letrozole63%Anastrozole32%Exemestane6%Part D≥102 patients+ 10 more classes in this area
Blood & clotting
17.2%Erythropoiesis-stimulating Agent16.9%Darbepoetin alfa100%Part B, office-administered≥11 patientsFactor Xa inhibitor0.2%Xarelto51%Eliquis49%Part D≥16 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”